Actualités Pivotal Therapeutics Inc (CE) - PVTTF | Actions OTCMarkets

First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100

First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100 PR Newswire WOODBRIDGE, ON, June 4, 2015 WOODBRIDGE, ON...

Pivotal Therapeutics Announces First Quarter Financial Results

Pivotal Therapeutics Announces First Quarter Financial Results PR Newswire WOODBRIDGE, ON, June 1, 2015 WOODBRIDGE, ON, June 1, 2015 /PRNewswire/...

Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel

Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel PR Newswire WOODBRIDGE, May 11, 2015 WOODBRIDGE...

Pivotal Therapeutics Announces 2014 Financial Results

Pivotal Therapeutics Announces 2014 Financial Results PR Newswire WOODBRIDGE, ON, April 30, 2015 WOODBRIDGE, ON, April 30, 2015 /PRNewswire/...

Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and ...

Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and support...

Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial™ line of products in Korea

Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial™ line of products in Korea PR Newswire WOODBRIDGE...

Pivotal Therapeutics and French University Hospital of Strasbourg Announce POMEGA Trial Chief Investigator Dr. Yannick Georg ...

Pivotal Therapeutics and French University Hospital of Strasbourg Announce POMEGA Trial Chief Investigator Dr. Yannick Georg Laureate of EUR...

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients T...

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes...

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients T...

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes...

Pivotal Therapeutics announces payment of interest on outstanding convertible notes

Pivotal Therapeutics announces payment of interest on outstanding convertible notes PR Newswire WOODBRIDGE, ON, March 26, 2015 WOODBRIDGE, ON...

Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Age...

Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Agents (Statins...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pivotal Therapeutics Inc (CE) (PVTTF)

Outils de qualité professionnelle, pour des investisseurs individuels.

PVTTF Actualités

First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100

Pivotal Therapeutics Announces First Quarter Financial Results

Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel

Pivotal Therapeutics Announces 2014 Financial Results

Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and ...

Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial™ line of products in Korea

Pivotal Therapeutics and French University Hospital of Strasbourg Announce POMEGA Trial Chief Investigator Dr. Yannick Georg ...

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients T...

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients T...

Pivotal Therapeutics announces payment of interest on outstanding convertible notes

Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Age...

Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100

Pivotal Therapeutics: Year in Review and CEO Update

Pivotal Therapeutics announces payment of interest on outstanding convertible notes

VASCAZEN® POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pivotal Therapeutics Inc (CE) (PVTTF) Actualités

Pivotal Therapeutics Inc (CE) (PVTTF)

Outils de qualité professionnelle, pour des investisseurs individuels.

PVTTF Actualités

First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100

Pivotal Therapeutics Announces First Quarter Financial Results

Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel

Pivotal Therapeutics Announces 2014 Financial Results

Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and ...

Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial™ line of products in Korea

Pivotal Therapeutics and French University Hospital of Strasbourg Announce POMEGA Trial Chief Investigator Dr. Yannick Georg ...

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients T...

Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients T...

Pivotal Therapeutics announces payment of interest on outstanding convertible notes

Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Age...

Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100

Pivotal Therapeutics: Year in Review and CEO Update

Pivotal Therapeutics announces payment of interest on outstanding convertible notes

VASCAZEN® POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Abonnez-vous à un compte ADVFN en remplissant le formulaire ci-dessous!

Supprimer les publicités